High hepatitis B virus screening rate among patients receiving systemic anticancer treatment in Japan
| Autor: | T. Yamauchi, S. Yazaki, T. Higashi |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
0301 basic medicine Hepatitis B virus medicine.medical_specialty HBsAg Guanine medicine.medical_treatment Antineoplastic Agents medicine.disease_cause Targeted therapy 03 medical and health sciences 0302 clinical medicine Japan Neoplasms Internal medicine Odds Ratio medicine Humans Mass Screening Hepatitis B Antibodies Aged Aged 80 and over Chemotherapy Hepatitis B Surface Antigens business.industry Antibodies Monoclonal Cancer Hematology General Medicine Entecavir Odds ratio Middle Aged Antigens CD20 Hepatitis B medicine.disease Cancer registry 030104 developmental biology Oncology 030220 oncology & carcinogenesis Female Virus Activation Surgery business medicine.drug |
| Zdroj: | International Journal of Clinical Oncology. 25:1327-1333 |
| ISSN: | 1437-7772 1341-9625 |
| DOI: | 10.1007/s10147-020-01655-4 |
| Popis: | Patients with hepatitis B virus (HBV) infection have a risk of reactivation after chemotherapy. All patients undergoing chemotherapy should be screened for HBV infection. No large-scale studies have been conducted to examine HBV screening practice in Japan. We analyzed health insurance claims equivalent data linked with a nationwide hospital-based cancer registry. Patients diagnosed with cancer in 2014, who were aged 20 years and older and those who underwent systemic anticancer treatment in 2014–15 were included. We assessed the HBV screening rates by the HBsAg or anti-HBc tests, HBV-DNA tests, and entecavir prescriptions. Multiple logistic regression models were used to identify factors related to the receipt of screening. Of 177,597 patients (mean [SD] age, 65.6 [12.2] years), 82.6% and 12.9% patients had a solid tumor and hematologic malignancy, respectively. Among them, 88.1%, 6.3%, and 5.5% received cytotoxic chemotherapy, targeted therapy, and anti-CD20 antibodies, respectively. Overall, 70.6% of patients were screened. The positive predictor of HBV screening was receiving anti-CD20 antibodies [odds ratio (OR); 2.23, 95% confidence interval (CI) 2.06–2.41, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink